exhibited a modest increase, while ~40% experienced an increase of greater than 2-fold.
INTRODUCTION
The surfaces of mammalian cells are covered with a dense layer of carbohydrates, collectively known as the glycocalyx, that influence many aspects of the interaction between a cell and its microenvironment. To date, the biosynthesis of cell surface displayed glycans has been thought to be controlled largely by individual glycosyltransferases based on the assumption that flux through the metabolic pathways that supply activated nucleotide sugar donors (the substrates for these enzymes) is not a limiting factor. For example, this premise has been used in mathematical models of sialylation (1) , where concentrations of CMP-Neu5Ac in the lumen of the Golgi were assumed to be much higher than the K m of sialyltransferases (2) . In the past several years, the idea that nucleotide sugars, exemplified by CMP-Neu5Ac (shown in Fig. 1A ), are not a limiting or controlling factor in glycosylation has garnered one major and unambiguous exception, notably that changes in flux through the hexosamine biosynthetic pathway (HBP) can alter UDP-GlcNAc levels with profound consequences on the branching of N-linked glycans (3) .
By changing the valency of these glycoconjugates, flux through the HBP can alter the galectin lattice and affect a host of downstream biological events including cancer progression (4); cell differentiation and proliferation (3); and autoimmunity, metabolic syndromes, and aging (5) .
In this report, we demonstrate that the HBP is not unique in its ability to control surface glycoproteins via bulk metabolic flux. In particular, counter to earlier assumptions that flux through the sialic acid pathway does not significantly alter the sialylation of individual glycans (2) , analysis of two "high-demand" sialoglycans (i.e., polysialylated NCAM (6) and podocalyxin (7) ) suggested that fluctuations in the intracellular concentrations of sialic acid and the corresponding supply of CMP-Neu5Ac critically affected their production. In the current report, we used a global cell level approach to investigate whether these two examples were outliers or whether metabolic flux controls the surface display of sialic acid with fine resolution across a wide range of N-linked glycoproteins. We found that the sialylation of certain N-linked glycoproteins increased dramatically (e.g., by 5 to 8-fold) when flux through the sialic acid pathway was enhanced by exogenously-supplied substrate while there was negligible effect on other glycoproteins. Importantly, these changes altered the adhesive behavior of cancer cells in a manner consistent with the glycoproteomic analysis. Together, these findings expand the role of metabolic flux in controlling glycosylation beyond the HBP and provide a foundation to explore the hypothesis that cancer cells modulate their metastatic potential and malignant progression via changes to bulk metabolic flux through the sialic acid biosynthetic pathway.
EXPERIMENTAL PROCEDURES

Materials: Adhesion Molecules, Antibodies, and Reagents
E-selectin-IgG Fc (E-selectin) L-selectin-IgG Fc (L-selectin), P-selectin-IgG Fc (P-selectin), and unlabeled anti-CD44 mAbs (2C5) were purchased from R & D Systems (Minneapolis, MN).
Alkaline phosphatase (AP)-and horseradish peroxidase (HRP)-conjugated anti-mouse IgG and AP-conjugated anti-rat IgM were from Southern Biotech (Birmingham, AL). Unlabeled anti-CD44 mAbs (515), and HECA 452, were purchased from Abcam (Cambridge, MA). Functional anti-integrin α6 mAbs (GoH3) was purchased from Novus Biologicals (Littleton, CO).
Fluorescein labeled Sambucus nigra Lectin (SNA) and Ricinus communis agglutinin I (RCA)
were purchased from Vector Labs, (Burlingame, CA) and the FITC-conjugated Maackia amurensis agglutinin (MAA) lectin was from EY Laboratories (San Mateo, CA). All other reagents were from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.
Cell Culture
The human pancreatic carcinoma cell line SW1990 was obtained from the American Type Culture Collection (Manassas, VA) and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum and 1.0% (v/v) of a 100x stock solution of penicillin and streptomycin (Invitrogen, Carlsbad, CA). Prior to cell lysis, pancreatic cells were detached from culture flasks using Enzyme Free Cell Dissociation Media (20 min at 37 °C; Chemicon, Phillipsburg, NJ). CHO cells stably transfected with full-length E-selectin (CHO-E) or with phosphatidylinositol glycan-linked extracellular domain of P-selectin (CHO-P) were kindly donated by Affymax (Palo Alto, CA) and cultured as described previously (8) . Synthesis of 1,3,4-O-Bu 3 ManNAc followed a previously reported procedure (9) .
Periodate Resorcinal Assay
Total and bound sialic acid were quantified by the periodate resorcinol method. Briefly, treated and non-treated SW1990 cells were harvested with Enzyme Free Cell Dissociation Media and counted. The cells (2.25 x 10 6 ) were washed twice with 1.0 ml D-PBS (Dulbecco's phosphate-buffered saline), pelleted, resuspended in 200 μl D-PBS and divided into two 100 μl aliquots. Cell lysates were obtained by four freeze/thaw cycles; the lysates were then analyzed by the method of Jourdian and coworkers (10) adapted for a 96-well plate format (11) .
Oxidation of aliquots of each sample was performed in parallel at 0°C and 37°C to measure total sialic acid or glycoconjugate-bound sialic acid (note that CMP-sialic acid, although soluble, is detected in the what has conventionally been termed the "glycoconjugate-bound" fraction in this assay), respectively. Sialic acid concentrations were calculated by comparison with a standard curve (0-250 μM sialic acid) and expressed as the fold change from the control.
Lectin and Antibody Analysis of SW1990 Cells
Surface sialic acid was analyzed by labeling with fluorescein-conjugated Ricinus communis Agglutinin I (RCA), FITC-conjugated Maackia amurensis agglutinin (MAA), and fluoresceinconjugated Sambucus nigra agglutinin (SNA) lectins. In brief, 500,000 SW1990 cells were harvested as described above, washed with D-PBS, and resuspended in 100 µl D-PBS. Lectin (4.0 µl at 0.1 mg/ml) was added and the cell-lectin suspension was incubated for 1.0 h. Excess lectin was removed by washes with 1.0 ml D-PBS and the cells were analyzed by flow cytometry as described previously (12 
Western Analysis of CD44
Proteins (12 µg) were resolved by SDS-PAGE and transferred electrophoretically onto a nitrocellulose membrane. The membrane was blocked with 5% non-fat milk/0.1% TBS-Tween 20 at RT for 2.0 h and then probed with anti-human CD44 antibody (515) at 1:1000 at 4°C overnight, followed by three washes with 0.1% TBS-Tween 20. HRP-conjugated anti-mouse
IgG antibody was added at 1:2000 and incubated at RT for 1.0 h, followed by three washes with 0.1% TBS-Tween 20. The signal was visualized using SuperSignal Substrate (Pierce, Rockford, IL).
Mass Spectroscopy and Glyocopeptide Identification
Replicates of SW1990 cells (9 x 10 6 ) with or without treatment with 1,3,4-O-Bu 3 ManNAc were harvested and lysed using RIPA buffer (Sigma-Aldrich) according to the manufacturer's instructions. The protein concentration was determined using the BCA assay (Pierce); 1.4 mg of protein was used in following experiment for each cell treatment condition. Urea (8.0 M) and TCEP (5.0 mM) were added to each sample to the indicated final concentrations followed by incubation at 60°C for 2.0 h. Iodoacetamide (10 mM final concentration) was added to each sample and they were incubated for 30 min at RT in the dark. Each solution was diluted 8-fold with 100 mM KH 2 PO 4 (pH 8.0). Trypsin (Promega, 30 μg) was added to each sample followed by incubation at 37°C overnight with shaking. Silver staining was used to monitor the completeness of trypsin digestion as indicated by the disappearance of high MW protein bands and the appearance of lower MW peptide bands (< 10 kDa). After digestion, the samples were centrifuged at 16,110 x g for 5.0 min to remove particulate matter.
The peptides were cleaned by elution through a C18 column and divided into two equal parts, N-linked total glycopeptides were then isolated from one sample using the solid phase extraction of glycopeptides (SPEG) method (13) (14) (15) . This method was modified to extract N-linked sialoglycopeptides from the second aliquots of each sample. Briefly, the modified SPEG method used 1.0 mM pre-cooled sodium periodate at 0°C for 15 min to oxidize sialic acid selectively.
The resulting sialoglycopeptides were covalently conjugated to a solid support via hydrazide chemistry while non-sialylated glycopeptides were removed by washing prior to release of N- The hash may be used to prove exactly what files were published as part of this manuscript's data set, and the hash may also be used to check that the data has not changed since publication. For single peptide identification, the matched spectra can be found in Supplementary Table 2 .
KEGG Pathway Analysis of Identified Glycoproteins
The DAVID Bioinformatics Resources 6.7 tool (National Institute of Allergy and Infectious Diseases, NIAID, NIH) was used to analyze the glycoproteins and sialoglycoproteins identified in the present study and assign them into categories compiled by the KEGG database. All analysis parameters were used in the default setting.
Evaluation of the Cut-off of the Protein Abundance Ratio for Protein Changes
To correct for any systematic errors of protein ratio introduced by sample handling and to determine the appropriate cut-off for protein changes, the distribution of abundance ratios of glycosylation changes was generated. Since the majority of proteins were not expressed differently in two cell states, we normalized the ratio based on the distribution of the protein abundance ratios from two cell states. Proteins that fell outside the normal distribution from the abundance ratio of two cell states were considered as altered proteins. The threshold to select protein changes was based on the ratio distribution of two cell states. The mean and standard deviation of ratio from two cell states were calculated, and the abundance of proteins with an abundance ratio outside of one standard deviation from the mean were flagged as altered.
Flow-based Adhesion Assays
To simulate the physiological shear environment of the vasculature, pancreatic carcinoma cells in D-PBS containing Ca +2 /Mg +2 , 0.1% BSA were perfused over immobilized E-, or Lselectin-coated dishes at prescribed wall shear stresses using a parallel plate flow chamber (250-µm channel depth, 5.0-mm channel width). Adhesion was quantified by perfusing cells at 1.0 x 10 6 /ml and recording for 2 or 5 min. Average rolling velocities were computed as the distance traveled by the centroid of the translating cell divided by the time interval at the given wall shear stress (16) .
Blot Rolling Assays
SW1990 whole cell lysate was prepared by membrane disruption using 2.0% Nonidet P-40
followed by differential centrifugation. Blots of immunopurified CD44 from treated and untreated SW1990 whole cell lysate were stained with anti-CD44 (2C5) or anti-CD44 (515) 
Surface Plasmon Resonance Binding Assay
Surface plasmon resonance (SPR) binding studies were performed using a BIAcore 3000 system (BIAcore Inc., Piscataway, NJ). Recombinant human E-, L-, and P-selectin-Fc chimera 
Modeled Representations of Identified Glycopeptides in the Overall Structures of CD44 and Integrin α6
For CD44, the identified glycan was modeled onto the NMR structure of CD44 (PDB ID:1UU), using the program GlyProt (http://www.glycosciences.de/glyprot/) (17) . Because a corresponding structure is not available for integrin α6, the structure of the integrins αV (PBD ID: 3ije) was used to model the subunit repeat of the propeller where the identified glycopeptide was located using a comparative protein structural modeling approach (18) . The GlycoProt program was used to N-glycosylate the model subunit with a simplified N-glycan structure.
Visualization of structures was done with the Chimera software (19) .
Statistical Analysis
Data are expressed as the mean S.E. for at least three independent experiments. Statistical significance of differences between means was determined by analysis of variance. analog-driven flux through the sialic acid pathway. It is noteworthy that the analysis of nonsialylated epitopes (e.g., CD15 (Fig. 2G) ) indicated that analog-enhanced flux through the sialic pathway did not simply saturate all possible sites of sialic acid attachment because if it did, CD15 levels would be reduced to the levels observed in the isotype control. Once we established that bulk flux through the sialic acid pathway in SW1990 cells altered surface sialic acid display, we used mass spectrometry-based methods to identify the specific sites of glycosylation associated with these changes and then investigated whether these changes resulted in altered cell behavior, as described below. (Table 1) .
Glycoproteomic Analysis of Metabolic Flux-driven Changes to N-Glycan Sialylation
Together, these results verified that this analog gave rise to sialic acid specific changes while leaving N-glycan levels unchanged.
Several noteworthy trends observed from the glycoproteomic analyses are summarized in (Fig. 4A) .
Because not all sialoglycopeptides exhibited an increase and the ones that did had a distinct biomodal distribution, we divided these samples into three groups for further analysis: Group 1, statistically unchanged sialylation; Group 2, modestly increased sialylation; and Group 3, substantially increased sialylation.
Pathway Analysis Revealed that Group 2 "Modestly Increased" Sialoglycoproteins Include Adhesion Molecules (e.g., CD44 and Integrin α6) implicated in Metastasis
David pathway analysis was used to assign the glycopeptides identified from the mass spectrometry data to pathways delineated by the KEGG database. This analysis revealed that the total sets of proteins identified from both of the N-glycan and sialic acid-specific capture methods fit into 13 pathway classes that were distributed very similar to each other (Fig. 4B ).
The comparison of these two data sets revealed that each profile consisted of 12 categories (listed in Fig. 4C ) with the main difference a complete absence of proteins in the hypertrophic cardiomyopathy class (xiii) in the N-linked set and an absence of hypertrophic myopathy (ix) proteins in the sialylated set.
A more detailed analysis of the three groups of sialylated glycoproteins (i.e., Group 1, 2, and 3 from Fig. 4A ) revealed that Groups 1 and 3 had a fairly broad distribution of pathway categories (Fig. 4D) . By contrast, Group 2 proteins were restricted to 4 of the 13 categories with two of these categories (v, cell adhesion molecules; and xii, renin angiogensis system) completely absent from the unchanged (Group 1) and highly increased (Group 3) sialoglycoproteins.
Flux-driven Sialylation of CD44 and Integrin α6 Enhances Adhesion Associated with Metastasis
We reasoned that the "Group 2" proteins might be restricted to a modest, but real, increase in sialylation because they were involved in critical cellular processes very sensitive to changes in this PTM. The identification of CD44 and integrin α6 in this category (Table 1) provided an opportunity to test whether any of the sialic acid-specific changes identified in the glycoproteomic data had a meaningful impact on cell behavior because of these molecules involvement in cancer progression and metastasis (23) (24) (25) . Metastasis is a multi-step process in (Fig. 5A) . A smaller, but still statistically significant, decrease was noted for L-selectin-dependent rolling under the same shear conditions (Fig. 5B) consistent with prior work showing that CD44 possesses ligand activity for both of these selectins (27-29). Importantly, the site density of CD44 expressed in the analog-treated cells did not increase, as assessed by flow cytometry (Fig. 5C ) and western blot analysis (Fig. 5D) implicating the increased sialylation of these molecules as the sole factor contributing to the efficiently with E-selectin relative to controls, we used surface plasmon resonance (SPR) to show that E-selectin rapidly and avidly bound to CD44 isolated from analog-treated SW1990 cells (Fig. 5F ). In contrast, only modestly increased affinity of CD44 isolated from 1,3,4-O- verifying that the observed changes in adhesion were specific to changes in sialic acid display.
DISCUSSION
In the past, two methods have been used to alter metabolic flux through the sialic acid pathway (Fig. 1A) and both have had limitations. One has been the manipulation of GNE, an enzyme that regulates flux into the sialic acid pathway (31, 32). GNE, however, is a multifunctional protein that modulates the transcription of enzymes involved in glycosylation (33) and it also interacts directly with cell adhesion molecules (34) in multiple ways that could affect the endpoints evaluated in this study. Alternately, the sialic acid pathway can be supplemented with exogenous ManNAc but the high levels needed (often in the tens of millimolar (11)) are problematic while more efficiently utilized peracetylated analogs (35) have significant and often deleterious side effects (36) . The current study avoided these problems by employing the "high flux" tri-butanoylated analog 1,3,4-O-Bu 3 ManNAc that allows intracellular sialic acid levels to be elevated to high levels (9) with negligible cytotoxicity or perturbation to gene regulation (37, 38) . In this study, treatment of SW1990 cells with 1,3,4-O-Bu 3 ManNAc increased total sialic acid levels several fold and impacted glycoconjugate-bound and surface sialylation more modestly (e.g., by ≤ 2-fold) when measured using lectins or antibodies at celllevel resolution (Fig. 2) .
Having confirmed that globally increased surface sialylation occurred in 1,3,4-OBu 3 ManNAc-treated SW1990 cells, we conducted a glycoproteomic analysis ( hematopoietic stem cell lineages, and xii, renin angiogensis system, Fig. 4D ).
An intriguing explanation for the fairly restricted subset of "Group 2" glycoproteins ( Fig.   4D ) that experienced tightly regulated increases in sialylation was that the activities of these proteins are unusually sensitive to sialylation. Accordingly, while cells are able to increase their sialylation thereby moving them out of "Group 1", tight regulation is required to prevent their activity from being modified too severely, thus preventing them from moving into "Group 3".
Alternately, there may be no need to increase sialylation too greatly because even modest increases can modulate biological activities. We obtained experimental evidence for the latter premise by demonstrating that the sialylation status of CD44 and integrin α6, which are members of the cell adhesion category of tightly regulated proteins (i.e., "v" in the David pathway analysis, Fig. 4 ), contributed to changes in cancer cell mobility consistent with the known role of sialic acid in these processes. For example, increased sialylation of CD44 resulted in enhanced binding to selectins (Fig. 5) ; cancer cells exploit selectin-mediated adhesion to exit the vascular during metastasis. Another way sialylation assists metastasis is through integrinmediated adhesion that facilitates cell migration through the ECM. We measured this endpoint via a wound healing assay wherein analog-treated SW1990 cells showed an increased ability to migrate across ECM components (Fig. 6) . It is noteworthy that the increased mobility of analogtreated cells on ECM components complements enhanced selectin-mediated adhesion to facilitate two distinct facets of metastasis, namely the (i) tethering and rolling and (ii) firm adhesion steps of the extravasation process.
Of the multiple potential sites of N-glycosylation for CD44 and integrin α6 that may have affected the activity of these molecules, we identified one site for CD44 and two for integrin α6
that were selectively hypersialated in cells treated with 1,3,4-O-Bu 3 ManNAc. Two of these three changes occurred in domains of the host proteins previously implicated in adhesion and provide the new information that sialic acid attached to a specific site of N-glycosylation is an important determinant of adhesion. These two sites are the hyaluronan binding domain of CD44 (Fig. 7A) (39) the propeller domain of an integrin (Fig. 7B ) (40) . Although the impact of the increased sialylation observed for the third glycopeptide, located in the Calf-2 domain of integrin α6 ( 
